Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

BACKGROUND: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaziano, J. Michael, Cincotta, Anthony H., Vinik, Aaron, Blonde, Lawrence, Bohannon, Nancy, Scranton, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541616/
https://www.ncbi.nlm.nih.gov/pubmed/23316290
http://dx.doi.org/10.1161/JAHA.112.002279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541616/
https://www.ncbi.nlm.nih.gov/pubmed/23316290
http://dx.doi.org/10.1161/JAHA.112.002279

Ejemplares similares